Enckelmann 1991.

Methods	1. Randomized 2. Double blind 3. Three parallel groups ‐ placebo ‐ Alprazolam 1.5‐4 mg/d ‐ Buspirone 15‐40 mg/d 4. Duration: 6 weeks with a 3‐7 day washout period with placebo prior 5. Analysis: data from patients still in the study at the time point (week 2, 4, or 6) included in the analysis
Participants	1. Diagnosis: GAD (DSM‐III) 2. N = 94 Age (mean and range): 35 (19‐65) Sex: 49% females Setting: outpatients History: excluded any significant psychiatric disorder other than GAD
Interventions	1. Placebo (N = 31) 2. Alprazolam (N = 32) 3. Buspirone (N = 31
Outcomes	1. dropout rates 2. HAM ‐A 3. HAM‐D 4. Raskin Depression Scale 5. Covi‐Anxiety Scale 6. SCL 90 7. Physician Global Improvement Scale
Notes	(a) CGI scores not entered into final analysis as data not available (b) HAM‐A scores not included into final analyses as means and SDs not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear